Table 3. Univariate and multivariate analyses for overall survival.
BMI, body mass index; HR, hazard ratio; NACT; neoadjuvant chemotherapy; NLR, neutrophil-to-lymphocyte ratio; PDS; primary debulking surgery; FIGO: International Federation of Gynecology and Obstetrics; CA-125: cancer antigen-125; LG includes endometrioid carcinoma, clear cell carcinoma, mucinous carcinoma, and low-grade serous carcinomas; HG includes high-grade serous carcinomas.
| Characteristics | Category | Univariate | Multivariate | |
| P-value | HR (95% CI) | P-value | ||
| Age | ≥47 vs. <47 years | 0.712 | 0.65 (0.32-1.32) | 0.230 |
| Parity | Multiparous vs. nulliparous | 0.031 | 2.32 (1.11-4.84) | 0.025 |
| Menopausal status | Postmenopause vs. premenopause | 0.927 | - | - |
| BMI | ≥24.0 vs. <24.0 kg/m2 | 0.795 | - | - |
| Serum CA-125 levels | ≥112.0 vs. <112.0 U/mL | 0.662 | - | - |
| Comorbidity | Yes vs. no | 0.749 | - | - |
| Upfront primary treatment | NACT vs. PDS | 0.657 | - | - |
| Ascites | Yes vs. No | 0.284 | 1.05 (0.53-2.07) | 0.900 |
| FIGO stage | Advanced vs. early | 0.507 | - | - |
| Surgical debulking status | Optimal vs. suboptimal | 0.944 | - | - |
| Histological subtype | HG vs. LG | 0.470 | 1.22 (0.57-2.60) | 0.615 |
| Pretreatment NLR | ≥1.93 vs. <1.93 years | 0.013 | 2.23 (1.08-4.61) | 0.031 |